Mechanical thrombectomy treatment is cost-effective for patients with stroke: Medtronic study
06 November 2024 | News
First dedicated industry sponsored registry on the use of mechanical thrombectomy devices in patients for acute ischemic stroke (AIS)
image credit- shutterstock
Medtronic, a global leader in healthcare technology, has unveiled results from the Prospective Registry for Assessment of Acute Ischemic Stroke Patients Treated with stroke Devices in India (PRAAN) at the World Stroke Congress 2024, held in Abu Dhabi.
PRAAN is India’s first industry-sponsored dedicated registry on mechanical thrombectomy, collecting real-world data on the use of stroke devices in patients with acute ischemic stroke (AIS) caused by large vessel occlusion.
The multi-centre study evaluates the clinical outcomes associated with market-released stroke devices of Medtronic for AIS patients with large vessel occlusion condition.
The PRAAN registry enrolled 200 patients over 24 months, across 14 centres, and demonstrated that mechanical thrombectomy is a safe, effective, as well as cost-effective treatment for AIS in India.
The data from the PRAAN study demonstrated high rates of positive functional outcomes and procedural success of mechanical thrombectomy with a low mortality rate in AIS patients. Additionally, the health economic analysis revealed that mechanical thrombectomy (MT) alone or in combination with intravenous tissue plasminogen activator (IV-tPA) appears to be cost-effective compared to IV-tPA treatment alone.
Discussing the PRAAN registry, Mandeep Singh Kumar, Vice President and Managing Director, Medtronic India, said, “Stroke is the fourth leading cause of death in India, making it one of the top non-communicable diseases in the country. PRAAN is a first-of-its kind multi-centric prospective stroke clinical registry in India that tracks and reports on mechanical thrombectomy. We are confident that the data and outcomes from the study will help ignite critical discourse to raise awareness about the dangers of stroke and available treatment pathways and will empower healthcare professionals and policy makers alike in providing the right resources and guidance for the Indian public.”
